(lp0
S'Galectin Therapeutics Issues Statement Regarding GALTW and GALTU Nasdaq - Mar 23, 2017 NORCROSS, Ga., March 23, 2017  -- Galectin Therapeutics Inc. , the leading developer of therapeutics that target galectin proteins, announced today that trading will be halted in GALTW and GALTU at close of business on ...Trading in certain Galectin warrants ends today; trading in stock unaffected - Seeking Alpha'
p1
aS'Galectin Therapeutics Inc. Announces Pricing of Public Offering of 1159445 ... Business Wire  - Mar 23, 2012 NEWTON, Mass.----Galectin Therapeutics Inc.  today announced the pricing of an underwritten public offering of 1,159,445 units at a price to the public of $9.00 per unit, with each unit consisting of two common voting&nbsp;...'
p2
aS'Morning Top News: Galectin Therapeutics, Inc. , Time Inc. (NYSE ... Benchmark Monitor - Mar 27, 2017 Unit holders had the right at any time to separate each GALTU unit into two shares of GALT common stock and one publicly traded warrant, and most unit holders exercised that right. Galectin Therapeutics, Inc.  shares ticked up 3.29% to&nbsp;...'
p3
aS'GALECTIN THERAPEUTICS INC.  Files An 8-K Entry into a Material ... Market Exclusive - Dec 29, 2016 Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer.'
p4
aS'Galectin Therapeutics, Inc.  Insider Ownership stands at 11.7 The Newburgh Press - Feb 23, 2017 Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer.Earnings Guidance on Galectin Therapeutics Inc. - Energy Index'
p5
aS'analysts Recommendations: Galectin Therapeutics, Inc.  News Oracle - Feb 7, 2017 Galectin Therapeutics, Inc.  will report its next earnings on Mar 13 - Mar 17 . The company reported the earnings of $-0.19/Share in the last quarter where the estimated EPS by analysts was $-0.22/share. The difference between the&nbsp;...'
p6
aS"Bull Market Ahead for the Biotech Industry in 2017? Today's Reports on Sarepta ... Yahoo Finance - Feb 22, 2017 Galectin Therapeutics shares spiked 31.97 percent to close at $1.94 a share on Tuesday. The stock traded between $1.47 and $1.94 on volume 1.85 million shares traded."
p7
aS'Gainers &amp; Losers Of The Day: EYES, SGNL, NEOT, DMTX, MBRX... Nasdaq - Feb 8, 2017 Non-transferable subscription rights to purchase units, composed of a share of Second Sight common stock and a five-year warrant to purchase an additional share of common stock, will be issued in the offering.'
p8
aS'Allergan to buy Tobira in push for fatty liver disease drugs Reuters - Sep 20, 2016 Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity. Just ...'
p9
aS"Profil Institute Unites Leading Experts In Biomarker Discovery And Clinical ... Clinical Leader - Oct 29, 2015 Profil Institute is partnering with KineMed, Inc., a drug discovery and development company, and Dr. Rohit Loomba, founding director of UC San Diego's NAFLD Translational Research Unit and founder and principal investigator of the San Diego Integrated&nbsp;..."
p10
a.